The importance of handling high-value biologicals: Physico-chemical instability and immunogenicity of monoclonal antibodies (Review)

Laptoš,Tomislav; Omersel,Jasna

doi:10.3892/etm.2018.5821

The importance of handling high-value biologicals: Physico-chemical instability and immunogenicity of monoclonal antibodies (Review)

Authors:
- Tomislav Laptoš
- Jasna Omersel
View Affiliations

Affiliations: Pharmacy Unit, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia, Chair of Clinical Biochemistry, Faculty of Pharmacy, University of Ljubljana, 1000 Ljubljana, Slovenia
Published online on: January 31, 2018 https://doi.org/10.3892/etm.2018.5821
Pages: 3161-3168

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present review specifies the various chemical and physical factors that can influence drug stability and immunogenicity, and the treatment outcomes of antibody biologicals. Although monoclonal antibodies (mAbs) are known to be more resistant to environmental changes compared with other proteins, the molecules themselves can be subjected to chemical and physical processes that promote their degradation and transformation into their specific amino‑acid moieties. With increasing use of medicinal products that contain mAbs, and their self‑administration by the patients, the issue of the correct manipulation of these drugs is of increasing importance. This review summarises the correct handling of mAb biologicals from the point of view of the pharmacist, clinical biochemist and patient, as is supported by relevant cases from the literature and our own data and experience. In particular, if there is a break in the cold chain, both healthcare professionals and patients need to be aware of the potential pharmacokinetics and pharmacodynamics alterations to these biologicals. Furthermore, any alterations in the protein structure can induce harmful immune reactions, including anaphylaxis and cytokine storms, or result in the production of neutralising or blocking Abs. Overall, considering also that treatment costs usually remain high, drug stability can have a tremendous effect on the clinical, humanistic and economic outcomes of such treatments.

View Figures

View References

1	Das G and Rees A: Use of monoclonal antibodies for proprotein convertase subtilisin kexin type 9 inhibition: Issues with efficacy, tolerability and safety. Curr Opin Lipidol. 25:96–98. 2014. View Article : Google Scholar : PubMed/NCBI
2	Elvin JG, Couston RG and van der Walle CF: Therapeutic antibodies: Market considerations, disease targets and bioprocessing. Int J Pharm. 440:83–98. 2013. View Article : Google Scholar : PubMed/NCBI
3	Shukla D, Schneider CP and Trout BL: Molecular level insight into intra-solvent interaction effects on protein stability and aggregation. Adv Drug Deliv Rev. 63:1074–1085. 2011. View Article : Google Scholar : PubMed/NCBI
4	Wang W: Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm. 185:129–188. 1999. View Article : Google Scholar : PubMed/NCBI
5	Berrill A, Biddlecombe J and Bracewell D: Product quality during manufacture and supplyPeptide and protein delivery. Chris Van Der W: Academic Press; Boston, MA: pp. 313–339. 2011, View Article : Google Scholar
6	Kamerzell TJ, Esfandiary R, Joshi SB, Middaugh CR and Volkin DB: Protein-excipient interactions: Mechanisms and biophysical characterization applied to protein formulation development. Adv Drug Deliv Rev. 63:1118–1159. 2011. View Article : Google Scholar : PubMed/NCBI
7	Bee JS, Nelson SA, Freund E, Carpenter JF and Randolph TW: Precipitation of a monoclonal antibody by soluble tungsten. J Pharm Sci. 98:3290–3301. 2009. View Article : Google Scholar : PubMed/NCBI
8	Davies MJ: The oxidative environment and protein damage. Biochim Biophys Acta. 1703:93–109. 2005. View Article : Google Scholar : PubMed/NCBI
9	Margiloff L, Chaplia L, Chow A, Singhal PC and Mattana J: Metal-catalyzed oxidation of immunoglobulin G impairs Fc receptor-mediated binding to macrophages. Free Radic Biol Med. 25:780–785. 1998. View Article : Google Scholar : PubMed/NCBI
10	Liu D, Ren D, Huang H, Dankberg J, Rosenfeld R, Cocco MJ, Li L, Brems DN and Remmele RL Jr: Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation. Biochemistry. 47:5088–5100. 2008. View Article : Google Scholar : PubMed/NCBI
11	Mian IS, Bradwell AR and Olson AJ: Structure, function and properties of antibody binding sites. J Mol Biol. 217:133–151. 1991. View Article : Google Scholar : PubMed/NCBI
12	Dimitrov JD, Ivanovska ND, Lacroix-Desmazes S, Doltchinkova VR, Kaveri SV and Vassilev TL: Ferrous ions and reactive oxygen species increase antigen-binding and anti-inflammatory activities of immunoglobulin G. J Biol Chem. 281:439–446. 2006. View Article : Google Scholar : PubMed/NCBI
13	Omersel J, Jurgec I, Cucnik S, Kveder T, Rozman B, Sodin-Semrl S and Bozic B: Autoimmune and proinflammatory activity of oxidized immunoglobulins. Autoimmun Rev. 7:523–529. 2008. View Article : Google Scholar : PubMed/NCBI
14	Daugherty AL and Mrsny RJ: Formulation and delivery issues for monoclonal antibody therapeutics. Adv Drug Deliv Rev. 58:686–706. 2006. View Article : Google Scholar : PubMed/NCBI
15	Huang L, Lu J, Wroblewski VJ, Beals JM and Riggin RM: In vivo deamidation characterization of monoclonal antibody by LC/MS/MS. Anal Chem. 77:1432–1439. 2005. View Article : Google Scholar : PubMed/NCBI
16	Vermeer AW and Norde W: The thermal stability of immunoglobulin: Unfolding and aggregation of a multi-domain protein. Biophys J. 78:394–404. 2000. View Article : Google Scholar : PubMed/NCBI
17	Liu H, Gaza-Bulseco G and Sun J: Characterization of the stability of a fully human monoclonal IgG after prolonged incubation at elevated temperature. J Chromatogr B Analyt Technol Biomed Life Sci. 837:35–43. 2006. View Article : Google Scholar : PubMed/NCBI
18	Ye H: Simultaneous determination of protein aggregation, degradation, and absolute molecular weight by size exclusion chromatography-multiangle laser light scattering. Anal Biochem. 356:76–85. 2006. View Article : Google Scholar : PubMed/NCBI
19	Segura A, Herrera M, González E, Vargas M, Solano G, Gutiérrez JM and León G: Stability of equine IgG antivenoms obtained by caprylic acid precipitation: Towards a liquid formulation stable at tropical room temperature. Toxicon. 53:609–615. 2009. View Article : Google Scholar : PubMed/NCBI
20	Arakawa T, Prestrelski SJ, Kenney WC and Carpenter JF: Factors affecting short-term and long-term stabilities of proteins. Adv Drug Deliv Rev. 46:307–326. 2001. View Article : Google Scholar : PubMed/NCBI
21	Wang W, Nema S and Teagarden D: Protein aggregation-pathways and influencing factors. Int J Pharm. 390:89–99. 2010. View Article : Google Scholar : PubMed/NCBI
22	Hawe A, Kasper JC, Friess W and Jiskoot W: Structural properties of monoclonal antibody aggregates induced by freeze-thawing and thermal stress. Eur J Pharm Sci. 38:79–87. 2009. View Article : Google Scholar : PubMed/NCBI
23	Wang W: Lyophilization and development of solid protein pharmaceuticals. Int J Pharm. 203:1–60. 2000. View Article : Google Scholar : PubMed/NCBI
24	Chang BS, Kendrick BS and Carpenter JF: Surface-induced denaturation of proteins during freezing and its inhibition by surfactants. J Pharm Sci. 85:1325–1330. 1996. View Article : Google Scholar : PubMed/NCBI
25	Cleland JL and Langer R: Formulation and Delivery of Proteins and Peptides: Design and Development Strategies. (ACS Symposium Series 567). American Chemical Society; Washington, DC: 1994, View Article : Google Scholar
26	Hermeling S, Crommelin DJ, Schellekens H and Jiskoot W: Structure-immunogenicity relationships of therapeutic proteins. Pharm Res. 21:897–903. 2004. View Article : Google Scholar : PubMed/NCBI
27	Rosenberg AS: Effects of protein aggregates: An immunologic perspective. AAPS J. 8:E501–E507. 2006. View Article : Google Scholar : PubMed/NCBI
28	De Groot AS and Scott DW: Immunogenicity of protein therapeutics. Trends Immunol. 28:482–490. 2007. View Article : Google Scholar : PubMed/NCBI
29	Keiserman M, Codreanu C, Handa R, Xibillé-Friedmann D, Mysler E, Briceño F and Akar S: The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: Practical consequences. Expert Rev Clin Immunol. 10:1049–1057. 2014. View Article : Google Scholar : PubMed/NCBI
30	Schellekens H and Jiskoot W: Eprex-associated pure red cell aplasia and leachates. Nat Biotechnol. 24:613–614. 2006. View Article : Google Scholar : PubMed/NCBI
31	Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD and Panoskaltsis N: Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 355:1018–1028. 2006. View Article : Google Scholar : PubMed/NCBI
32	Hwang WY and Foote J: Immunogenicity of engineered antibodies. Methods. 36:3–10. 2005. View Article : Google Scholar : PubMed/NCBI
33	Joubert MK, Hokom M, Eakin C, Zhou L, Deshpande M, Baker MP, Goletz TJ, Kerwin BA, Chirmule N, Narhi LO and Jawa V: Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J Biol Chem. 287:25266–25279. 2012. View Article : Google Scholar : PubMed/NCBI
34	Brinks V, Jiskoot W and Schellekens H: Immunogenicity of therapeutic proteins: The use of animal models. Pharm Res. 28:2379–2385. 2011. View Article : Google Scholar : PubMed/NCBI
35	Swanson SJ and Bussiere J: Immunogenicity assessment in non-clinical studies. Curr Opin Microbiol. 15:337–347. 2012. View Article : Google Scholar : PubMed/NCBI
36	Breckenridge A: Report of the working party on the addition of drugs to intravenous infusion fluids (HC(76)9). Department of Health and Social Security; London: 1976
37	Langford S, Fradgley S, Evans M and Blanks C: Assessing the risk of handling monoclonal antibodies. Hospital Pharm. 15:60–64. 2008.
38	Odou P: Medical devices for safe handling of cytotoxic drugs. Eur J Oncol Pharm. 4:17–19. 2010.
39	Paul M, Vieillard V, Jaccoulet E and Astier A: Long-term stability of diluted solutions of the monoclonal antibody rituximab. Int J Pharm. 436:282–290. 2012. View Article : Google Scholar : PubMed/NCBI
40	Grundstein A, Meentemeyer V and Dowd J: Maximum vehicle cabin temperatures under different meteorological conditions. Int J Biometeorol. 53:255–261. 2009. View Article : Google Scholar : PubMed/NCBI
41	Laguerre O and Flick D: Temperature prediction in domestic refrigerators: Deterministic and stochastic approaches. Int J Refrigeration. 33:41–51. 2010. View Article : Google Scholar
42	James SJ, Evans J and James C: A review of the performance of domestic refrigerators. J Food Eng. 87:2–10. 2008. View Article : Google Scholar